Staphylococcal Superantigen-Like (SSL) proteins, one of major virulence factor 8 families produced by Staphylococcus aureus, were previously demonstrated to be immune 9 64 are the Staphylococcal superantigen-like proteins (SSLs) (16). 65 SSLs are a family of 14 proteins with structural similarity to Staphylococcal 66 SSL13 activates human neutrophils via FPR2 superantigens but lack the functional T-cell receptor binding domain and therefore exhibit 67 no superantigenic activity (17). Moreover, structurally, the C-terminal β-grasp domain of 68 these SSL proteins show homology to other staphylococcal immune evasion proteins like 69 CHIPS. SSL1 to SSL11 are encoded on staphylococcal pathogenicity island 2 whereas 70 SSL12, SSL13 and SSL14 are found on the immune evasion cluster 2 (IEC-2) (4, 18). The 71 SSL gene cluster is conserved in all human and animal isolates of S. aureus examined to 72 date, indicating that it is very stable and evolutionary important cluster for the organism 73 (18-20). Furthermore, antibodies against the SSLs are detected in human serum, indicating 74 that they are expressed in vivo and may play a role during infection (20, 21). Even though 75 the SSLs are highly conserved and involved in innate immune evasion, they have distinct 76 functions (17). It was reported previously that several SSL members located on the main 77 cluster (SSL3, SSL5, SSL6, SSL7 and SSL10) are involved in inhibition of host immune 78 responses (22-25). SSL3 and SSL4 have been described as Toll-like receptor 2 (TLR2) 79
were put on ice and incubated with anti-CD11b and anti-CD62L mAb for 45 min on ice.
186
Cells were washed and fixed with 1% PFA in buffer. Expression of CD11b and CD62L was 187 measured on a flow cytometer and data expressed relative to the buffer treated cells.
188
Calcium flux in neutrophils and HL-60 cells. Calcium flux with isolated human 189 neutrophils and HL-60 cells was performed in a flow cytometer as previously described (31).
190
Briefly, cells at 5 x 10 6 cells/ml were labeled with 0.5 µM Fluo-3-AM ester, washed and 191 resuspended to a concentration of 1x10 6 cells/ml. To measure cells continuously and be able injected into the peritoneum of 6-to 8-week-old female CD-1 mice. At 4 hours later, the 225 mice were euthanized by cervical dislocation and abdominal cavities washed with two times 226 5 ml of RPMI medium containing 0.1% HSA and 5mM EDTA. In total 8 to 9 ml of 227 peritoneal fluid was recovered and centrifuged at 1200 rpm for 10 min to collect the exudate 228 cells. Cell pellets were resuspended in 500 µl buffer and counted with trypan blue in a TC20 229 automated cell counter (BioRad). Before immuno staining, cells were first preincubated with 230 100 µg/ml normal goat IgG for 15 min. We stained the samples with APC-conjugated 231 antibody to mouse CD45 (leukocytes marker), PE-conjugated antibody to mouse Gr1 232 (neutrophil marker), and FITC-conjugated antibody to mouse F4/80(macrophage marker).
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Samples were analyzed on a flow cytometer.
234
Mouse neutrophils were isolated from bone marrow as described previously (36). Percoll density gradient (2 ml each in PBS) composed of 81% and 62.5% was used to 238 enrich neutrophils from the total leucocyte population. Interphase between between 62.5% and 81% was collected. Cells were washed once with buffer and resuspended in 240 PRMI1640 with 0.1% HSA.
241
Calcium fluxes in mouse neutrophils were determined as described above for human identified proteins, 12 (20%) were described to play a role in host microbe interaction. Of 272 these 11 were already functionally characterized and for 1 protein, SSL13, no known 273 function has been described. The fact that SSL13 was identified in this selection suggests 274 that it is involved in binding to neutrophils or its components.
275

SSL13 specifically interacts with human neutrophils 276
To confirm that SSL13 interacts directly with human neutrophils, a three-fold dilution 277 series of recombinant SSL13 with an N-terminal His tag was incubated with human 278 leukocytes isolated from healthy donors. His-tagged SSL7 and SSL5 were included as 279 negative and positive control neutrophil-binding proteins respectively (7, 37). We observed 280 that SSL13 interacts with human neutrophils and monocytes in a dose dependent manner, 281 but no significant binding was observed to lymphocytes ( Fig. 1A-C) . CD11b and simultaneously down-regulated the expression of CD62L in a dose-dependent 289 manner ( Fig. 2A-B ). In addition to the altered expression of surface adhesion molecules, 290 activated neutrophils also exhibit intracellular release of calcium (40). We therefore 291 measured the intracellular release of calcium after neutrophil exposure to a range of SSL13 292 concentrations (23-740 nM). In concordance with the cell receptor expression assay, our 293 calcium flux data showed that SSL13 induces a transient dose-dependent release of Ca 2+ in 294 neutrophils ( Fig. 2C-D) . Degradation of SSL13 by proteinase K completely abolished the 295 neutrophil activation indicating that the observed activation is not caused by a non-protein 296 contaminant in the SSL13 preparation ( Fig. S3 A-D antagonists of neutrophil GPCRs were tested, including those for formyl peptide receptor 1 309 (FPR1) and 2 (FPR2), Leukotriene B4 receptor, platelet activating factor (PAF) receptor,
310
Complement C5a receptor, and the IL-8 receptors CXCR1 and CXCR2. We found that the 311 FPR2 antagonists FLIPr inhibited the SSL13 induced calcium mobilization as well as the 312 binding to human neutrophils ( Fig. 3B-C) . Although FLIPr also slightly inhibits the FPR1 313 activation, the control protein CHIPS, that specifically inhibits FPR1 (11), had no effect on 314 SSL13-mediated neutrophil activation (Fig. 3C ). Together, these experiments indicate that 315 SSL13 elicits calcium fluxes in human neutrophils via FPR2.
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To further confirm that FPR2 is the receptor for SSL13, we used HL60 cells stably 317 transfected with or without human FPR2 (45, 46) . Binding of FITC-labeled SSL13 was only 318 observed with HL60/FPR2 and not with control HL60 cells (Fig. 3D ). Furthermore, in order 319 to evaluate the role of FPR2 in recognizing SSL13, we analyzed the intracellular Ca 2+ 320 response to SSL13 of HL60 with or without FPR2. Fig. 3E shows that SSL13 induces a 321 profound calcium flux in HL60/FPR2, but not in untransfected HL60 cells. The activation 322 potential of SSL13 is comparable to the specific FPR2 agonistic peptide MMK-1 (Fig. 3E ).
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Moreover, SSL13 activates the FPR2 transfected HL60 cells in a dose dependent manner 324 (Fig. 3F) . Finally, the induced calcium flux of the FPR2 transfected HL60 cells by SSL13 325 and MMK-1 can be inhibited by the FPR2-specific inhibitor FLIPr (Fig. 3G) . These findings 326 confirm that SSL13 specifically binds and activates cells via FPR2. (Fig. 4A) . Moreover, the SSL13 induced chemotaxis in human neutrophils can be 334 blocked by the FPR2 antagonist FLIPr (Fig. 4B) .
335
A common feature of most GPCRs is that they not only strongly activate the 336 chemotactic migration of neutrophils, but also trigger neutrophil oxidative burst and 337 degranulation. To examine whether SSL13 is involved in FPR2-induced oxidative burst, a 338 Reactive Oxygen Species (ROS) assay was performed. The peptides WKYMVM and 339 MMK-1 can both induce FPR2-mediated ROS production, although WKYMVM is more 340 potent and was therefore used as control in our experiment (48). Our data shows that SSL13 341 induced a modest oxidative burst compared with the control FPR2 specific peptide 342 WKYMVM (Fig. 4C ), but both SSL13-and WKYMVM-induced oxidative burst in human 343 neutrophils could be blocked by FLIPr (Fig. 4C ). Furthermore, we tested whether SSL13 Indeed, SSL13 induces neutrophil degranulation (Fig. 4D) . Taken together, the functional 348 outcomes of SSL13-induced neutrophil activation include chemotaxis, ROS production and 349 neutrophil degranulation pointing toward a pro-inflammatory response of neutrophils to this staphylococcal protein.
351
To test whether SSL13 could act intracellular and are produced by S.aureus after uptake 352 by human neutrophils, we generated a GFP promoter construct. Since SSL13 is part of indicates that the neutrophil activation by SSL13 happened in a murine FPR2 dependent 364 manner (Fig. 5A ), although much higher concentrations are needed as compared to human 365 neutrophil activation (Fig. 5B) . In contrast, the specific FPR2 agonistic peptide WKYMVM 366 showed similar activation ability to both human and murine neutrophils (Fig. 5C ). However,
367
we are unable to detect any SSL13 binding to murine neutrophils (data not shown).
368
Since there was a minimal but specific activation of mouse neutrophils, we tested 369 whether SSL13 can provoke a neutrophil influx after injection of SSL13 into the mouse- 
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The SSLs are a family of 14 secreted proteins which were previously demonstrated to 390 modulate immune evasion (3, 4, 17) . Genetic analyses of 88 clinical S. aureus strains 391 revealed that the genes encoding SSL12, SSL13, and SSL14 are conserved among all strains 392 (51). We also confirm that SSL13 is produced in vivo as antibodies against those proteins 393 can be detected in human serum (Fig. S4 ). Furthermore, in sharp contrast to the SSLs 
